Niagen Bioscience shares rise 21.05% in premarket after Q4 revenue and EPS exceed estimates, full-year net sales grow 30% to $129.4M, net income up 103% to $17.4M, and expansion of market reach with new product launches.

Niagen Bioscience surged 21.05% in premarket trading, driven by Q4 earnings and full-year growth exceeding estimates, along with new product launches and expanded market reach in Asia and the EU. The company reported Q4 revenue of $33.8 million (vs. expected $31.7 million) and adjusted EPS of $0.03 (vs. expected $0.02). For 2025, net sales reached $129.4 million (up 30%), net income hit $17.4 million (up 103%), and gross margin rose to 64.3%. The firm also launched Tru Niagen Beauty, plans to release an at-home Niagen Plus injection kit, and expanded its presence to over 1,200 health clinics in Asia and the EU.